Multimodal Strategy Improves Ovarian Cancer Detection

This article originally appeared here.
Share this content:
Multimodal Strategy Improves Ovarian Cancer Detection
Multimodal Strategy Improves Ovarian Cancer Detection

WEDNESDAY, May 13, 2015 (HealthDay News) -- Screening with a multimodal strategy (MMS) in which annual serum cancer antigen 125 (CA-125) is interpreted with the risk of ovarian cancer algorithm (ROCA), improves detection of invasive epithelial ovarian or tubal cancers (iEOCs), according to a study published online May 11 in the Journal of Clinical Oncology.

Usha Menon, M.D., from University College London, and colleagues conducted incidence screening in 46,237 women, aged 50 years or older, using the MMS strategy. Women were classified according to ROCA and treated accordingly: normal risk, returned to annual screening; intermediate risk, repeat CA-125; and elevated risk, repeat CA-125 screening and transvaginal ultrasound.

The researchers found that 133 of the 640 women who underwent surgery had primary iEOCs. Twenty-two interval iEOCs occurred within one year of screening, one of which was detected by ROCA and managed conservatively. For detection of iEOCs, the sensitivity and specificity of MMS were 85.8 and 99.8 percent, respectively, with 4.8 surgeries per iEOC. Of the iEOCs, 87.1 percent were detected with ROCA alone. Using fixed cutoffs for CA-125 of >35, >30, and >22 U/mL, 41.3, 48.4, and 66.5 percent would have been detected, respectively. Compared with the single threshold rule, the area under the curve for ROCA was significantly higher (0.915 versus 0.869; P = 0.0027).

"In the context of cancer screening, reliance on predefined single-threshold rules may result in biomarkers of value being discarded," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »